ConductScience.org, home

Comparison · NCT00523978-a5e21510

Cryoablation vs Standard Treatment With Drugs Only: Treatment Success

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Cryoablation vs Standard Treatment With Drugs Only: Treatment Success. Trial comparisons, record NCT00523978-a5e21510. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00523978-a5e21510

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6990.6250.765wilson
Risk in group 20.07320.0340.151wilson
Risk difference, group 1 minus group 20.6260.5190.702newcombe hybrid score
Risk ratio, group 1 over group 29.564.420.8log
Odds ratio, group 1 over group 229.51272.2log
Number needed to treat, for one more participant with the outcome on Cryoablation than on Standard Treatment With Drugs Only1.61.421.93from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1CryoablationExperimental group or subjects that were cryoablated with Arctic Front® Cardiac CryoAblation Catheter System, including the FlexCath® Steerable Sheath and Freezor® MAX Cardiac Cryoablation Catheter114163OG000
Group 2Standard Treatment With Drugs OnlyA control group receiving only an Atrial Fibrillation Drug who have not previously failed a AF study drug.682OG001

Outcome

Type
PRIMARY
Title
Treatment Success
Description
Treatment Success was defined as Acute Procedure Success (APS) and freedom from Chronic Treatment Failure (CTF) for Experimental Subjects, and freedom from CTF for Control Subjects. Under this pre-specified definition of Treatment Success, Experimental Subjects must have had APS and remained free of CTF during the 12-month follow-up duration, while Control Subjects must have remained free of CTF during the 12-month follow-up duration.
Time frame
12 months
Population
The mITT population consisted of all subjects, who were enrolled, randomized and received treatment

Source ClinicalTrials.gov

Trial

Title
A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation
NCT number
NCT00523978
Phases
PHASE3
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Arctic Front® Cryoablation Catheter, Flecainide or Sotalol or Propafenone
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Results first posted
2012-08-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00523978-a5e21510